Drug manufacturer, Allergan, announced the FDA approval of BOTOX Cosmetic (OnabotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe forehead lines. This is the third approval awarded to the BOTOX brand of neurotoxin, which had previously been approved only for the cosmetic treatment of crow’s feet and glabellar (“elevens”) lines. While the approval comes as no surprise to most Undercover Agents, it is surprising to learn that BOTOX Cosmetic is the only neurotoxin brand to receive approval of aesthetic indications beyond glabellar lines in the U.S. (competitors, Dysport and Xeomin, are more limited in their FDA-approved uses).
“Allergan recognizes that forehead lines are a top area of concern for patients,” says David Nicholson, Chief Research and Development Officer at Allergan. “Our goal in pursuing a third indication for BOTOX Cosmetic for the temporary improvement in the appearance of moderate to severe forehead lines was based on our desire to study the patient selection, dosing and injection pattern to help provide optimal treatment outcomes.” Approved for use in over 75 countries, BOTOX Cosmetic is the most widely researched and studied treatment of its kind.